• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    TransMedics Group (TMDX) Is Up 5.6% After Raising 2026 Revenue Guidance Despite EPS Compression

    Simply Wall St·08/15/2026 18:25:33
    Listen to the news
    • In early August 2026, TransMedics Group reported second-quarter revenue of US$189.95 million and net income of US$14.68 million, with lower earnings per share than the same period a year earlier.
    • Despite profit compression, the company raised the low end of its full-year 2026 revenue guidance to a range of US$737 million to US$757 million, signaling confidence in its top-line trajectory.
    • Next, we’ll examine how the raised full-year revenue guidance reshapes TransMedics’ existing investment narrative around transplant network expansion.

    AI is about to change healthcare. These 44 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

    TransMedics Group Investment Narrative Recap

    To own TransMedics, you need to believe its Organ Care System and integrated transplant network can keep gaining share without eroding profitability too far. The latest quarter did not change the near term story much: solid revenue growth but sharply lower earnings per share keep margin pressure front and center, while the main catalyst remains execution on transplant network expansion. The key risk right now is that rising costs outpace revenue progress and squeeze earnings further in upcoming quarters.

    Against that backdrop, the August decision to raise the low end of 2026 revenue guidance to US$737 million to US$757 million stands out. It links directly to the transplant network expansion catalyst, suggesting management still sees enough procedural volume and OCS adoption to support higher full year revenue, even as net income for the first half of 2026 (US$22.0 million) is well below the prior year’s US$60.6 million and margin recovery is not yet evident.

    Yet beneath this confidence, investors should be aware that growing regulatory and public scrutiny of organ procurement practices could...

    Read the full narrative on TransMedics Group (it's free!)

    TransMedics Group's narrative projects $1.1 billion revenue and $192.7 million earnings by 2029. This requires 18.0% yearly revenue growth and a roughly $41 million earnings increase from $151.7 million today.

    Uncover how TransMedics Group's forecasts yield a $97.30 fair value, a 10% upside to its current price.

    Exploring Other Perspectives

    TMDX 1-Year Stock Price Chart
    TMDX 1-Year Stock Price Chart

    Some of the most optimistic analysts were previously banking on about US$1.1 billion of revenue and US$250 million of earnings by 2029, so this quarter’s margin compression and heavier investment needs might either reinforce that bullish view as a necessary trade off or prompt a rethink, depending on how you weigh those ambitious targets against the real risk of slower international adoption highlighted earlier.

    Explore 9 other fair value estimates on TransMedics Group - why the stock might be worth over 5x more than the current price!

    The Verdict Is Yours

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    • A great starting point for your TransMedics Group research is our analysis highlighting 4 key rewards that could impact your investment decision.
    • Our free TransMedics Group research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate TransMedics Group's overall financial health at a glance.

    Interested In Other Possibilities?

    The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.